ReviewFrontiers in pharmacology2022

Therapeutic potential of tucidinostat, a subtype-selective HDAC inhibitor, in cancer treatment.

Yichen Sun et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.